INZY Inozyme Pharma
- 4.510
- -0.030-0.66%
- 4.510
- 0.0000.00%
Inozyme Pharma News
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham
Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham
Inozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline Prospects
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)
Buy Rating on Inozyme Pharma Supported by Advancements in Lead Program and Promising Market Opportunities
Inozyme Pharma GAAP EPS of -$0.38 Beats by $0.02
Inozyme Pharma Q1 EPS $(0.38) Misses $(0.36) Estimate
Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 5 percent increase over losses of $(0.40)
Inozyme Pharma | 10-Q: Quarterly report
Inozyme Pharma: Runway To Fund Operations Into 4Q 2025 >INZY
Inozyme Pharma: Runway To Fund Operations Into 4Q 2025 >INZY
Inozyme Pharma 1Q Loss/Shr 38c >INZY
Inozyme Pharma 1Q Loss/Shr 38c >INZY
Press Release: Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights - Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiv
RMBS, SANM and WGS Are Among After Hour Movers
12 Health Care Stocks Moving In Monday's After-Market Session
GainersGeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free cash flow for the full fiscal year 2024.
Inozyme Pharma Is Maintained at Buy by B of A Securities
Inozyme Pharma Is Maintained at Buy by B of A Securities
B of A Securities Maintains Buy on Inozyme Pharma, Lowers Price Target to $14
B of A Securities analyst Tazeen Ahmad maintains Inozyme Pharma with a Buy and lowers the price target from $16 to $14.
Needham: Reiterates Inozyme Pharma (INZY.US) rating and adjusted from buy to buy rating, target price of $23.00.
Needham: Reiterates Inozyme Pharma (INZY.US) rating and adjusted from buy to buy rating, target price of $23.00.
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Needham analyst Joseph Stringer reiterates Inozyme Pharma with a Buy and maintains $23 price target.
Inozyme Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 298.61% Needham → $23 Reiterates Buy → Buy 03/13/2024 177.3% HC Wainwright & Co. $16 → $16 Main
Analysis
Price Target
No Data
